Recombinant Human IL-18BP protein (His Tag)

Species

Human

Purity

>90 %, SDS-PAGE

Tag

C-6*His

Activity

not tested

Cat no : Eg1147



Product Information

Purity >90 %, SDS-PAGE
Endotoxin <0.1 EU/μg protein, LAL method
Activity
Not tested
Expression HEK293-derived Human IL-18BP protein Thr31-Gly194 (Accession# O95998-2) with a His tag at the C-terminus.
GeneID 10068
Accession O95998-2
PredictedSize 18.4 kDa
SDS-PAGE 30-50 kDa, reducing (R) conditions
Formulation Lyophilized from 0.22 μm filtered solution in PBS, pH 7.4. Normally 5% trehalose and 5% mannitol are added as protectants before lyophilization.
Reconstitution Briefly centrifuge the tube before opening. Reconstitute at 0.1-0.5 mg/mL in sterile water.
Storage Conditions
It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
  • Until expiry date, -20℃ to -80℃ as lyophilized proteins.
  • 3 months, -20℃ to -80℃ under sterile conditions after reconstitution.
Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the recommended temperature.

Background

IL-18 binding protein (IL-18BP) is a natural regulatory molecule of the proinflammatory cytokine IL-18. IL-18BP gene is expressed in numerous types of tissues and cells of humans and animals and its expression is regulated by interferon gamma (IFN-gamma). It’s a glycoprotein belonging to the immune globulin superfamily. IL-18BP can effectively inhibit action of IL-18 in vivo and in vitro and is considered as a natural antagonist of IL-18. The imbalance of IL-18/IL-18BP has been noticed in some inflammatory diseases, including rheumatoid arthritis (RA), psoriasis, asthma, lupus erythematosus, multiple sclerosis, atherosclerosis, inflammatory bowel disease (IBD), Crohn’s disease (CD) and so on.

References:

1.Wang F.(2024). Biomed Rep. 9;20(6):87. 2.Muhl H, et al.(2000). Biochem Biophys Res Commun. 267:960–963. 3.Mazodier K, et al.(2005). Blood. 106:3483–3489. 4.Mochol M, et al.(2020). 80:221–225. 5.Park SY, et al.(2022). 10(7):1750.